Nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic Breast cancer: Results from the tnAcity trial

  1. Yardley, D.A.
  2. Coleman, R.
  3. Conte, P.
  4. Cortes, J.
  5. Brufsky, A.
  6. Shtivelband, M.
  7. Young, R.
  8. Bengala, C.
  9. Ali, H.
  10. Eakel, J.
  11. Schneeweiss, A.
  12. De La Cruz-Merino, L.
  13. Wilks, S.
  14. O’Shaughnessy, J.
  15. Glück, S.
  16. Li, H.
  17. Miller, J.
  18. Barton, D.
  19. Harbeck, N.
Revue:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Année de publication: 2018

Volumen: 29

Número: 8

Pages: 1763-1770

Type: Article

DOI: 10.1093/ANNONC/MDY201 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus